Amended Current Report Filing (8-k/a)
April 21 2023 - 4:01PM
Edgar (US Regulatory)
0001837412
true
0001837412
2023-03-24
2023-03-24
0001837412
SLGC:CommonStock0.0001ParValuePerShareMember
2023-03-24
2023-03-24
0001837412
SLGC:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember
2023-03-24
2023-03-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM
8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section
13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): March 24, 2023
SomaLogic, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
|
001-40090 |
|
85-4298912 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
2945
Wilderness Place, Boulder,
Colorado |
|
80301 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code:(303) 625-9000
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following
provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value per share |
|
SLGC |
|
The NASDAQ Stock Market LLC |
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share |
|
SLGCW |
|
The NASDAQ Stock Market LLC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
March 28, 2023, SomaLogic, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing
that, on March 28, 2023, the Board of Directors of the Company (the “Board”) had appointed Jason Ryan, Tom Carey, Kathy Hibbs,
and Tycho Peterson to serve as members of the Board. At the time of the Original 8-K, the Board had not determined the committees to which
the new members would be appointed. The disclosure contained in Item 5.02 of the Original Form 8-K is hereby supplemented and
amended by the disclosure contained in Item 5.02 of this Current Report on Form 8-K/A.
On
April 18, 2023, effective immediately, the Board made the following committee
appointments:
| ● | Ms.
Hibbs and Messrs. Ryan and Peterson were appointed as members of the Audit Committee. |
| ● | Mr.
Carey was appointed as a member of the Compensation Committee. |
| ● | Mr.
Carey was appointed as a member and chair of the Nominating and Corporate Governance Committee,
and Ms. Hibbs was appointed as a member of the Nominating and Corporate Governance Committee. |
Ms.
Hibbs and Messrs. Carey, Peterson, and Ryan will be compensated for each director’s
applicable appointments pursuant to the compensation program for non-employee directors,
as presently described under “Non-Employee Director Compensation” in the Company’s
proxy statement dated April 25, 2022 for its 2022 annual meeting of stockholders.
Item 9.01. Financial Statements and Exhibits.
Exhibit Number |
|
Exhibit Description |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SomaLogic, Inc.
(Registrant) |
|
|
|
|
By: |
/s/ Ruben Gutierrez |
|
Name: |
Ruben Gutierrez |
|
Title: |
General Counsel |
April 21, 2023
2
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From Oct 2024 to Nov 2024
CM Life Sciences II (NASDAQ:CMII)
Historical Stock Chart
From Nov 2023 to Nov 2024